# Suvorexant on Sleep Disturbance in Patients With Chronic Insomnia and Suboptimally Controlled Type 2 Diabetes

> **NCT03818581** · PHASE4 · COMPLETED · sponsor: **Massachusetts General Hospital** · enrollment: 108 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus
- Insomnia
- Sleep Disorder
- Inflammation

## Interventions

- **DRUG:** Suvorexant
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03818581
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-15
- **Primary completion:** 2021-11-03
- **Final completion:** 2021-11-03
- **Target enrollment:** 108 (ACTUAL)
- **Last updated:** 2024-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03818581

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03818581, "Suvorexant on Sleep Disturbance in Patients With Chronic Insomnia and Suboptimally Controlled Type 2 Diabetes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03818581. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*